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Abstract
Aromatase inhibitors effectively delay epiphysial maturation in boys and improve testosterone levels in adult men
Therefore, aromatase inhibitors may be used to increase adult height in boys with gonadotropin-independent
precocious puberty, idiopathic short stature and constitutional delay of puberty. Long-term efficacy and safety of
the use of aromatase inhibitors has not yet been established in males, however, and their routine use is therefore
not yet recommended.
Background
Over the past 15 years it has become evident that in
men estradiol is responsible for a number of effects ori-
ginally attributed to testosterone. Estradiol has an
important role in gaining and maintaining bone mass,
closing of the epiphyses and the feedback on gonadotro-
pin secretion. This fact became particularly evident in
men with aromatase deficiency. Aromatase is the
enzyme responsible for conversion of androgens to
estrogens. Men with estrogen deficiency caused by a
mutation in the CYP19 gene suffer from low bone
mineral density (BMD) and unfused epiphyses, and have
high gonadotropin and testosterone levels [1]. Estrogen
excess in turn has been associated with premature clo-
sure of the epiphyses, gynecomastia and low gonadotro-
pin and testosterone levels. Lowering estrogen levels in
men has emerged, consequently, as a potential treatment
for a number of disorders including pubertas praecox,
the andropause (also referred to as late-onset hypogo-
nadism) and gynecomastia. Aromatase inhibitors were
proven to be safe, convenient and effective for the treat-
ment of hormone sensitive breast cancer in women
although their use is associated with a modest increase
in bone resorption [2,3]. This review will discuss the
potential targets and the evidence for the use of aroma-
tase inhibitors in men and adds more recent data to the
text of an earlier review on this subject [4].
Metabolism of estrogens in men
Aromatase, also known as estrogen synthetase, is the
key enzyme in estrogen biosynthesis. The enzyme, loca-
lized in the endoplasmic reticulum of the estrogen-pro-
ducing cell, is encoded by the CYP19A1 gene. This gene
is a member of the CYP gene family, encoding a class of
enzymes active in the hydroxylation of endogenous and
exogenous substances. The CYP19A1 gene is localized
on chromosome 15 and comprises nine exons; the start
codon for translation is located on exon 2. Transcription
of the aromatase gene is regulated by several tissue-spe-
cific promoters. These promoters are under the influ-
ence of different hormones and growth factors such as
gonadotropins (gonadal promoter II) and interleukin-6,
interleukin-11 and tumor necrosis factor-a (adipose/
bone promoter I.4; for review see [5]). Aromatase activ-
ity has not only been demonstrated in gonads and pla-
centa but also in brain [6], fat tissue [7,8], muscle [9],
hair [10], bone [11] and vascular tissue [12].
Estradiol is the most potent estrogen produced in the
body. It is synthesized from testosterone or estrone via
aromatase or 17b-hydroxysteroid dehydrogenase, respec-
tively. The total estradiol production rate in the human
male has been estimated to be 35-45 μg (0.130-0.165
μmol) per day, of which approximately 20% is directly
produced by the testes [13,14]. Roughly 60% of circulat-
ing estradiol is derived from direct testicular secretion
or from conversion of testicular androgens. The remain-
ing fraction is derived from peripheral conversion of
adrenal androgens [15]. The mean estradiol plasma con-
centration in men is only about 1/200 of the mean
plasma testosterone concentration [16] and is
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early follicular phase of the menstrual cycle.
Phenotype of aromatase deficiency and excess
To date, eight males with aromatase deficiency have
been described: seven adults [17-23] and one newborn
[24]. Estradiol levels in these males were extremely low.
All adult aromatase-deficient men demonstrated a
remarkably low bone mass and unfused epiphyses lead-
ing to linear growth into adulthood and above-average
body length. Testicular size in these men ranged from
micro- to macroorchidism and the plasma testosterone
levels varied roughly in accordance with testis size.
Levels of luteinizing hormone (LH) were either normal
or elevated. Four men were infertile, in one younger
male fertility was not described. Two aromatase-defi-
cient men had a brother who also suffered from inferti-
lity despite a normal aromatase genotype, suggesting an
unrelated second condition. Once treated with estradiol,
epiphyses closed, BMD increased and disturbances in
the lipid profile improved in most of these patients.
On the other hand, several, mostly familial cases of aro-
matase excess have been reported. The clinical picture
consists of gynecomastia, accelerated growth and prema-
ture bone maturation due to excessive peripheral estrogen
synthesis. Stratakis et al. [25] described a family with aro-
matase excess syndrome in which the syndrome appeared
to be caused by inappropriately high expression of an
alternative first exon. Shozu et al. [26] described a father
and his son and one unrelated patient with aromatase
excess caused by a chromosomal rearrangement, which
placed the aromatase gene adjacent to cryptic promoters.
As a result an inappropriate amount of aromatase was
expressed in adipose tissue of the affected subjects.
These case reports illustrate the important contribu-
tion of estrogens to male health and identify the possi-
ble indications and risks of aromatase-inhibitor
treatment in men. Aromatase inhibitors may be used to
treat or prevent gynecomastia. They may be used to
increase gonadotropin secretion and thereby stimulate
Leydig and Sertoli cell function. Aromatase inhibitors
may be used to prevent or delay epiphysial closure and
thereby increase adult height. A major concern of aro-
matase inhibition is the possible detrimental effect on
bone mineralization.
Aromatase inhibitors
Aromatase inhibitors are classified as either steroidal or
nonsteroidal, or as first, second or third generation. Ster-
oidal inhibitors such as formestane and exemestane inhi-
bit aromatase activity by mimicking the substrate
androstenedione. Nonsteroidal enzyme inhibitors such as
anastrozole and letrozole inhibit enzyme activity by bind-
ing with the heme iron of the enzyme. First-generation
aromatase inhibitors such as aminoglutethimide are rela-
tively weak and nonspecific; they can also block other
steroidogenic enzymes necessitating adrenal steroid sup-
plementation. Third-generation inhibitors such as letro-
zole and anastrozole are potent and do not inhibit related
enzymes. They are well tolerated and apart from their
effects on estrogen metabolism their use does not appear
to be associated with important side effects in postmeno-
pausal women [27]. Although aromatase inhibition by
anastrozole and letrozole is reported to be close to 100%,
administration of these inhibitors to men will not sup-
press plasma estradiol levels completely. In men third-
generation aromatase inhibitors will decrease the mean
plasma estradiol/testosterone ratio by 77% [28,29]. This
f i n d i n gp r o b a b l yr e l a t e st ot h eh i g hp l a s m ac o n c e n t r a -
tions of testosterone, a major precursor for estradiol
synthesis in adult men. As aromatase inhibition is dose
dependent it has been suggested that aromatase is less
suppressed in the testis compared to adipose and muscle
tissue, explaining the incomplete efficacy of aromatase
inhibition in men. Aromatase activity is high in the testes
and the molar ratio of testosterone to letrozole is much
higher in the testes compared with adipose and muscle
tissue. When testicular testosterone and estradiol synth-
esis are suppressed and testosterone is administered exo-
genously in combination with letrozole, however, the
estradiol/testosterone ratio is suppressed by 81% [30],
which is only marginally different from the suppression
of this ratio in intact men after treatment with letrozole.
This incomplete suppression may be regarded as advan-
tageous for it prevents excessive reduction of estrogen
levels in men and the possible associated adverse effects.
In postmenopausal women with breast carcinoma, long-
term use of potent aromatase inhibitors reduces circulat-
ing estradiol levels by 88% [31] and is associated with
adverse effects on bone [2,3]. Due to the much higher
estrogen levels in treated men it remains to be deter-
mined whether this also holds true for men.
Effects of aromatase inhibition on luteinizing hormone
release and testosterone production
It is well known from experimental evidence and from
clinical observations that estradiol has powerful effects
on gonadotropin release in men. Modulation of plasma
estradiol levels within the male physiological range is
associated with strong effects on plasma levels of LH
through an effect at the level of the pituitary gland [32].
Lowering estradiol levels, by administering an aromatase
inhibitor, is associated with an increase in levels of LH,
follicle-stimulating hormone (FSH) and testosterone
[28,29]. Aromatase inhibitors, therefore, have been sug-
gested as a tool to increase testosterone levels in men
with low testosterone levels. Due to their mode of action
the use of aromatase inhibitors is limited to men with at
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tary-gonadal axis. Therefore aromatase inhibitors have
been tested in older men suffering from so-called late-
onset hypogonadism or partial androgen deficiency.
Aging in men is associated with a gradual decline of
total and free testosterone levels [33] as a result of com-
bined testicular and hypothalamic dysfunction. The
decline of testosterone levels has been implicated in the
pathogenesis of physical frailty in older men. Androgen
treatment, therefore, has been advocated for older men
with signs and symptoms of androgen deficiency and
unequivocally low plasma testosterone levels [34,35].
Aromatase inhibitors may be an attractive alternative
for traditional testosterone substitution in elderly men
because these compounds can be administered orally
once daily and may result in physiological 24 h testoster-
one profiles. Additionally, misuse of aromatase inhibitors
is unlikely since testosterone levels will not be stimulated
to vastly supraphysiological levels. A small, controlled
study demonstrated that anastrozole in a dose of 1 mg
daily during 12 weeks will result in doubling of the mean
bioavailable testosterone level in older men [36]. A more
recent study also showed a moderate but significant
effect of aromatase inhibitiono ne s t r a d i o la n dt e s t o s t e r -
one levels in older men [37]. Treatment with atamestane
100 mg once daily resulted in a 40% increase in total tes-
tosterone levels after 36 weeks. However, no beneficial
effects were seen on muscle strength, body composition
or quality-of-life scores. A similar increase of testosterone
levels in the absence of effects on body composition and
strength was reported in a study, in which elderly men
with borderline low levels of serum testosterone were
treated with anastrozole during 1 year [38]. There is a
number of possible explanations for the lack of a clear
treatment effect. First of all, the numbers of studied sub-
jects were relatively small. Moreover, the mean baseline
testosterone levels in the treated groups were in, or only
slightly below, the normal range for young adult men and
the relative increase in testosterone levels may have been
too small. It has been suggested that men with the lowest
baseline testosterone levels benefit most from testoster-
one substitution [39]. Finally, the decreased levels of
estradiol may have affected the expected rise in lean body
mass [38]. These observations outline a serious limitation
of the use of aromatase inhibitors in older men; the sti-
mulating effect on testosterone levels may be too weak,
especially in the men with the lowest baseline testoster-
one levels who would potentially benefit most.
Effects of aromatase inhibition in obese men
Peripheral androgen aromatization is enhanced in sub-
jects with increased body mass index [40]. Massively
obese men show markedly increased plasma estradiol
concentrations and low testosterone concentrations [41].
In three small studies, letrozole or testolactone has been
administered to morbidly obese men to improve their
testosterone levels [42-44]. Treatment resulted in nor-
malization of testosterone levels in all subjects, with a
concomitant suppression of t h eo r i g i n a l l yi n c r e a s e d
levels of estradiol. This normalization of the estradiol/
testosterone ratio might be of advantage, because of the
suppressive effects of testosterone on the expression of
the estrogen receptor b, which in itself, in the presence
of high levels of estradiol, can suppress the expression
of GLUT-4, leading to insulin insensitivity [45]. A case
study describes a morbidly obese infertile man, who
after a similar treatment with anastrozole showed a nor-
malized pituitary-testis axis, spermatogenesis and ferti-
lity [46]. However, testosterone levels will also improve
on weight loss [47], which is the intervention of choice
for obese men with or without low testosterone levels.
Effects of aromatase inhibition on release of follicle-
stimulating hormone and spermatogenesis
Although FSH release is primarily under the control of
inhibin, circulating estradiol has a substantial effect on
FSH levels in men [28]. Aromatase inhibition results in a
three-fold increase in levels of FSH [28,29] in eugonadal
men and may potentially stimulate sperm production.
Earlier studies using tamoxifen or clomifene to increase
FSH levels did not show unequivocal evidence for the
efficacy of this approach [48]. Uncontrolled studies using
anastrozole, testolactone or letrozole have shown some
evidence for a positive effect on sperm concentration and
motility [49-51]. However, one double-blind crossover
trial using testolactone did not show a significant
improvement of sperm quality in men with oligospermia
[52]. More recently, a study in which anastrozole was
added to the treatment with tamoxifen in men with idio-
pathic oligoasthenoteratozoospermia and a decreased tes-
tosterone over estradiol ratio after treatment with
tamoxifen alone indicated an increased pregnancy rate
compared with the group without the addition of the aro-
matase inhibitor [53]. Finally, pretreatment with aroma-
tase inhibitors was described to lead to positive results of
testicular sperm extraction in Klinefelter’ss y n d r o m e
patients with low pretreatment testosterone concentra-
tions: men from whose testes spermatozoa were retrieved
showed higher posttreatment testosterone levels and tes-
tosterone over estradiol ratios compared to men in
whom no spermatozoa could be obtained, whereas pre-
treatment levels of testosterone, LH and FSH did not pre-
dict the result of treatment outcome [54].
Effects of aromatase inhibition on bone metabolism and
epiphysial closure
Estrogens are essential for epiphysial maturation in boys.
Aromatase inhibitors, therefore, may be used to lower
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maturation. This approach proved successful in rare
conditions such as the aromatase-excess syndrome [25]
and high estrogen levels due to Sertoli cell tumors in
boys with Peutz-Jeghers syndrome [55]. In boys with
familial male precocious puberty due to activating muta-
tions of the LH receptor, also known as testotoxicosis,
treatment with an antiandrogen in combination with an
aromatase inhibitor to prevent effects on bone is the
treatment of choice. In an earlier study a combination
of spironolactone and testolactone proved effective [56],
whereas in later studies the combination of bicalutamide
and anastrozole was used [57-59].
Aromatase inhibition has also been studied in boys
with idiopathic short stature. Boys with a mean age of
11 years at the start of the study were treated with letro-
zole 2.5 mg once daily or placebo for 2 years [60].
Letrozole treatment was associated with higher plasma
levels of gonadotropins and testosterone in boys who
entered puberty during the study. In spite of this fact,
plasma estradiol levels were mostly lower in the letro-
zole-treated group. Both groups showed similar growth
velocity but bone age progressed significantly slower in
the letrozole group resulting in a gain of 5.9 cm in pre-
dicted adult height. The fact that growth velocity was
not affected is remarkable in the light of the observa-
tion, that in adult men treated with a combination of
testosterone and anastrozole the responses to GH secre-
tagogues were smaller than in men treated with a com-
bination of testosterone and a placebo; the GH and
IGF-1 concentrations were positively correlated with
estradiol levels [61]. Also in letrozole-treated boys in
whom treatment started at the beginning of puberty,
IGF-I levels were lower than in placebo-treated controls
[62]. As expected, GH-deficient boys treated with GH
and anastrozole showed a larger increase in height than
their GH only-treated controls [63].
Boys with constitutional delay of puberty are typically
small for their age and final adult height is often in the
low-normal range. These boys may be treated with
androgens to induce puberty.A l t h o u g ht e s t o s t e r o n e
induces growth velocity, the estrogens aromatized from
testosterone will accelerate epiphysial maturation and
for that reason reduce adult height further. The combi-
nation of testosterone and letrozole, therefore, was
tested in boys with constitutional delay of puberty. This
combination treatment effectively increased growth velo-
city but epiphysial maturation was slower in the letro-
zole-treated group, leading to a significant increase in
predicted adult height [64,65].
Effects of aromatase inhibition on male breast
Aromatase inhibitors are widely prescribed for hormone-
responsive breast carcinoma in postmenopausal women.
It is well known that aromatase inhibition results in a
dramatic reduction of tumor estrogen concentrations
[66]. As gynecomastia in men presumably results from
an imbalance between androgen and estrogen action,
aromatase inhibition was tested as a treatment for gyne-
comastia in boys. Treatment with anastrozole daily for 6
months, however, did not result in a significant improve-
ment compared with placebo [67]. This is in accordance
with the data summarized in a recent review [68],
describing similar responses to placebo, tamoxifen and
anastrozole in a number of observational studies. Ana-
strozole was also studied in a group of prostate cancer
patients treated with bicalutamide, an androgen antago-
nist. A dose of 1 mg daily appeared to be mildly effective
against the appearance of gynecomastia. Tamoxifen was
much more effective, however, in the prevention of gyne-
comastia in these men [69,70]. Due to these disappoint-
ing results, aromatase inhibitors are not recommended as
a first-line treatment for gynecomastia in men.
Data on treatment of male mammary tumors with
aromatase inhibitors are scarce and indicate that this
treatment modality is unlikely to be successful because
of the unwanted effect of increased levels of testoster-
one, making it impossible to reach the low estradiol
levels obtained in postmenopausal women after this
treatment [71]. The combination with a GnRH analog
in order to prevent this increase did not yield beneficial
results either [72].
Safety and concerns for aromatase inhibitors in men
Extensive experience with third-generation aromatase
inhibitors in postmenopausal women did not reveal
major side effects related to their use. Long-term use in
postmenopausal women is associated with a moderate
increase in bone resorption and a modest decrease in
BMD compared with placebo [2,3]. As outlined above,
low BMD is a characteristic sign of aromatase deficiency
but also in normal men most cross-sectional studies
showed that bioavailable or total estradiol levels are
associated with BMD [73-77]. The primary concern,
therefore, associated with aromatase inhibition in men is
the negative effect it may have on bone metabolism. In
most studies utilizing aromatase inhibitors in men estra-
diol levels decreased only moderately. Additionally, the
suppression of plasma estradiol levels in men is asso-
ciated with an increase in gonadotropin levels, which
stimulate the production of testosterone, the main pre-
cursor for estradiol synthesis. Khosla et al. [76,78] pro-
posed a threshold for bioavailable estradiol of 30 pM,
below which BMD appeared to be strongly and nega-
tively associated with the plasma bioavailable estradiol
concentration in men. Thresholds should be interpreted
with great caution because they rely heavily on the
methods used to measure total or bioavailable estradiol
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tion to measure bioavailable estradiol levels whereas if
they had calculated bioavailable estradiol levels using
the popular Sodergard equation [79,80] their proposed
threshold may have been as high as 75 pM. In experi-
mental settings, selective withdrawal of estradiol in men
was associated with an increase in markers of bone
resorption [30,81]. In the studies published so far aro-
matase inhibition in men did not appear to be asso-
ciated with adverse effects on bone in a number of
studies [37,59,82,83], but in a more recent study a
decrease of spine BMD was observed after one year of
treatment of elderly men with anastrozole [84]. Addi-
tionally, one short-term study did not show adverse
effects of aromatase inhibition in older men on cardio-
vascular markers. However, it is not clear that this con-
clusion also holds for boys: vertebral deformities were
observed in boys treated for delayed onset of puberty
[85]. Furthermore, hyperandrogenism induced by treat-
ment with aromatase inhibitors may result in decreased
HDL-cholesterol and increased hemoglobin levels [86],
indicating the need for follow-up during treatment. The
same group of investigators concluded that there were
no effects of letrozole on cognitive performance could
be detected in a group of prepubertal boys [87]. In a
group of elderly men who obtained exogenous testoster-
one enenthate, the addition of anastrozole to the
injected androgen prevented the androgen induced
improvement of verbal memory, but did not affect spe-
cial memory [88].
Conclusion
Over the years compelling evidence has accumulated
that in men estradiol has an important role in gaining
and maintaining bone mass, closing of the epiphyses
and feedback on gonadotrophin release. Aromatase inhi-
bitors, mostly combined with agonists of gonadotro-
phin-releasing hormone proved effective for the
prevention of premature epiphysial closure in boys with
pubertas praecox of various etiologies. There is also evi-
dence that aromatase inhibitors can be used in boys
with idiopathic short stature and boys with constitu-
tional delay of puberty to increase adult height. Aroma-
tase inhibitors are not effective for the treatment of
gynecomastia in pubertal boys and have limited efficacy
for the prevention of gynecomastia in bicalutamide-trea-
ted men with prostate cancer. Although aromatase inhi-
bitors increase FSH levels, there is no consistent
evidence for a beneficial effect on spermatogenesis. In
older men with so-called late-onset hypogonadism, aro-
matase inhibitors may emerge as an attractive alternative
for traditional testosterone supplementation to improve
testosterone levels. The long-term benefits of higher tes-
tosterone levels in older men remain controversial,
however. Moreover, it is questionable whether aroma-
tase inhibitors are able to stimulate testosterone produc-
tion sufficiently in men with truly low testosterone
levels for whom testosterone treatment is currently
recommended. Although most of the recent studies with
aromatase inhibitors in boys and adult men do not
show major detrimental effects on bone long-term skele-
tal safety remains an issue of concern.
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